ANAVEX LIFE SCIENCES CORP (AVXL) Fundamental Analysis & Valuation

NASDAQ:AVXL • US0327973006

Current stock price

3.07 USD
+0.25 (+8.87%)
At close:
2.97 USD
-0.1 (-3.26%)
After Hours:

This AVXL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. AVXL Profitability Analysis

1.1 Basic Checks

  • AVXL had negative earnings in the past year.
  • AVXL had a negative operating cash flow in the past year.
  • In the past 5 years AVXL always reported negative net income.
  • In the past 5 years AVXL always reported negative operating cash flow.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • AVXL has a Return On Assets of -30.04%. This is in the better half of the industry: AVXL outperforms 66.73% of its industry peers.
  • Looking at the Return On Equity, with a value of -31.55%, AVXL is in the better half of the industry, outperforming 74.66% of the companies in the same industry.
Industry RankSector Rank
ROA -30.04%
ROE -31.55%
ROIC N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • AVXL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. AVXL Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for AVXL has been increased compared to 1 year ago.
  • AVXL has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for AVXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 20.56 indicates that AVXL is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 20.56, AVXL belongs to the best of the industry, outperforming 89.56% of the companies in the same industry.
  • AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.56
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • AVXL has a Current Ratio of 20.87. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 20.87, AVXL belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
  • AVXL has a Quick Ratio of 20.87. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of AVXL (20.87) is better than 95.74% of its industry peers.
Industry RankSector Rank
Current Ratio 20.87
Quick Ratio 20.87
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AVXL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.36% over the past year.
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • AVXL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 64.04% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.61%
EPS Next 2Y31.74%
EPS Next 3Y84.57%
EPS Next 5Y64.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. AVXL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVXL. In the last year negative earnings were reported.
  • Also next year AVXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • AVXL's earnings are expected to grow with 84.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.74%
EPS Next 3Y84.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVXL Dividend Analysis

5.1 Amount

  • AVXL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVXL Fundamentals: All Metrics, Ratios and Statistics

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (3/31/2026, 6:25:50 PM)

After market: 2.97 -0.1 (-3.26%)

3.07

+0.25 (+8.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09
Earnings (Next)05-11
Inst Owners41.58%
Inst Owner Change15.81%
Ins Owners3.12%
Ins Owner Change0%
Market Cap284.50M
Revenue(TTM)N/A
Net Income(TTM)-39.95M
Analysts80
Price Target22.44 (630.94%)
Short Float %23.62%
Short Ratio13.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.31%
Min EPS beat(2)28.1%
Max EPS beat(2)46.52%
EPS beat(4)3
Avg EPS beat(4)20.05%
Min EPS beat(4)-9.44%
Max EPS beat(4)46.52%
EPS beat(8)6
Avg EPS beat(8)14.22%
EPS beat(12)10
Avg EPS beat(12)15.63%
EPS beat(16)12
Avg EPS beat(16)12.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.78%
EPS NY rev (1m)32.29%
EPS NY rev (3m)32.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.25
P/tB 2.25
EV/EBITDA N/A
EPS(TTM)-0.46
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS1.37
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.04%
ROE -31.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-35.72%
ROA(5y)-32.41%
ROE(3y)-39.37%
ROE(5y)-35.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.87
Quick Ratio 20.87
Altman-Z 20.56
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y38.61%
EPS Next 2Y31.74%
EPS Next 3Y84.57%
EPS Next 5Y64.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1044.8%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.25%
OCF growth 3YN/A
OCF growth 5YN/A

ANAVEX LIFE SCIENCES CORP / AVXL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ANAVEX LIFE SCIENCES CORP?

ChartMill assigns a fundamental rating of 3 / 10 to AVXL.


What is the valuation status for AVXL stock?

ChartMill assigns a valuation rating of 1 / 10 to ANAVEX LIFE SCIENCES CORP (AVXL). This can be considered as Overvalued.


How profitable is ANAVEX LIFE SCIENCES CORP (AVXL) stock?

ANAVEX LIFE SCIENCES CORP (AVXL) has a profitability rating of 1 / 10.